Non-steroidal anti-inflammatory drugs for the treatment of pain and immobility-associated osteoarthritis: Consensus guidance for primary care

BMC Family Practice

Volumn 13, Issue , 2012, Pages

  Adebajo, Ade ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT;

ARTICLE; CLINICAL PATHWAY; CONSENSUS DEVELOPMENT; DECISION SUPPORT SYSTEM; EVIDENCE BASED MEDICINE; FEMALE; GENERAL PRACTICE; HUMAN; MALE; OSTEOARTHRITIS; PAIN; PRACTICE GUIDELINE; RISK ASSESSMENT; SPECIALIZATION; STANDARD; UNITED KINGDOM; WALKING DIFFICULTY;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CONSENSUS DEVELOPMENT CONFERENCES AS TOPIC; CRITICAL PATHWAYS; CYCLOOXYGENASE 2 INHIBITORS; DECISION SUPPORT TECHNIQUES; EVIDENCE-BASED MEDICINE; FAMILY PRACTICE; FEMALE; GREAT BRITAIN; HUMANS; MALE; MOBILITY LIMITATION; OSTEOARTHRITIS; PAIN; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT; SPECIALIZATION;

EID: 84858390299     PISSN: None     EISSN: 14712296     Source Type: Journal    
DOI: 10.1186/1471-2296-13-23     Document Type: Article

References (34)

1. Royal College of General Practioners-Birmingham Research Unit, Annual prevalence report 2006 Accessed at http://www.rcgp.org.uk/pdf/ Annual%20prevalence%20report%202006.pdf on January 25, 2012
2. All cause and disease specific mortality in patients with knee or hip osteoarthritis: population based cohort study. Nuesch E, Dieppe P, Reichenbach S, Williams S, Iff S, Juni P, BMJ 2011 342 1165 10.1136/bmj.d1165 21385807
3. Comparative efficacy and safety of celecoxib and naproxen in the treatment of osteoarthritis of the hip. Kivitz AJ, Moskowitz RW, Woods E, Hubbard RC, Verburg KM, Lefkowith JB, Geis GS, J Int Med Res 2001 29 467 479 11803730 (Pubitemid 34036826)
4. Celecoxib versus diclofenac in the management of osteoarthritis of the knee. McKenna F, Borenstein D, Wendt H, Wallemark C, Lefkowith JB, Geis GS, Scand J Rheumatol 2001 30 11 18 10.1080/030097401750065265 11252686 (Pubitemid 32176218)
5. Evaluation of the functional status aspects of health-related quality of life of patients with osteoarthritis treated with celecoxib. Zhao SZ, McMillen JI, Markenson JA, Dedhiya SD, Zhao WW, Osterhaus JT, Yu SS, Pharmacotherapy 1999 19 1269 1278 10.1592/phco.19.16.1269.30879 10555933
6. Canadian consensus guidelines on long-term nonsteroidal anti-inflammatory drug therapy and the need for gastroprotection: benefits versus risks. Rostom A, Moayyedi P, Hunt R, Aliment Pharmacol Ther 2009 29 481 496 10.1111/j.1365-2036.2008.03905.x 19053986
7. National Institute for Health and Clinical Excellence (NICE), Osteoarthritis: The care and management of osteoarthritis in adults NICE clinical guideline 59 2008
8. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. Trelle S, Reichenbach S, Wandel S, Hildebrand P, Tschannen B, Villiger PM, Egger M, Juni P, BMJ 2011 342 7086 10.1136/bmj.c7086 21224324
9. EMEA statement following withdrawal of Vioxx (rofecoxib). European Medicines Agency, EMEA/97949/2004 London 2004
10. EMEA Public statement on the suspension of the marketing authorisation for Bextra (valdecoxib) in the European Union. European Medicines Evaluation Agency, EMEA/358324/2005 London 2005
11. European Medicines Agency recommends withdrawal of the marketing authorisations for lumiracoxib containing medicines. European Medicines Agency, EMEA/CHMP/579301/2007 London 2007
12. A group process model for problem identification and program planning. Delbecq AL, Vandeven AH, J Appl Behav Sci 1971 VII 466 491
13. An updated coronary risk profile. A statement for health professionals. Anderson KM, Wilson PW, Odell PM, Kannel WB, Circulation 1991 83 356 362 1984895
14. JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Joint British Societies, Heart 2005 91 Suppl 5 & 221 52 16365341
15. NHS Clinical Knowledge Service, Nonsteroidal anti-inflammatory drugs (standard or coxibs)-prescribing issues-Management. Who is at increased risk of gastrointestinal adverse effects from oral NSAIDs? 2008 Accessed at http://www.cks.nhs.uk/nsaids-prescribing-issues/management/detailed-answers/ gastrointestinal-adverse-effects/people-at-increased-risk on January 25, 2012
16. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. McGettigan P, Henry D, JAMA 2006 296 1633 1644 10.1001/jama.296.13.jrv60011 16968831 (Pubitemid 44511610)
17. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. Henry D, Lim LL, Garcia Rodriguez LA, Perez Gutthann S, Carson JL, Griffin M, Savage R, Logan R, Moride Y, Hawkey C, et al. BMJ 1996 312 1563 1566 10.1136/bmj.312.7046.1563 8664664 (Pubitemid 26188573)
18. The antiplatelet effect of six non-steroidal anti-inflammatory drugs and their pharmacodynamic interaction with aspirin in healthy volunteers. Gladding PA, Webster MW, Farrell HB, Zeng IS, Park R, Ruijne N, Am J Cardiol 2008 101 1060 1063 10.1016/j.amjcard.2007.11.054 18359332
19. Efficacy of opioids for chronic pain: a review of the evidence. Ballantyne JC, Shin NS, Clin J Pain 2008 24 469 478 10.1097/AJP.0b013e31816b2f26 18574357
20. Opioids for chronic musculoskeletal pain. Dunn KM, Hay EM, BMJ 2010 341 3533 10.1136/bmj.c3533 20605881
21. The comparative safety of analgesics in older adults with arthritis. Solomon DH, Rassen JA, Glynn RJ, Lee J, Levin R, Schneeweiss S, Arch Intern Med 2010 170 1968 1976 10.1001/archinternmed.2010.391 21149752
22. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. Hippisley-Cox J, Coupland C, BMJ 2005 330 1366 10.1136/bmj.330.7504.1366 15947398
23. Increased mortality and cardiovascular morbidity associated with use of nonsteroidal anti-inflammatory drugs in chronic heart failure. Gislason GH, Rasmussen JN, Abildstrom SZ, Schramm TK, Hansen ML, Fosbol EL, Sorensen R, Folke F, Buch P, Gadsboll N, et al. Arch Intern Med 2009 169 141 149 10.1001/archinternmed.2008.525 19171810
24. Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: a nationwide cohort study. Schjerning Olsen AM, Fosbol EL, Lindhardsen J, Folke F, Charlot M, Selmer C, Lamberts M, Bjerring Olesen J, Kober L, Hansen PR, et al. Circulation 2011 123 2226 2235 10.1161/CIRCULATIONAHA.110.004671 21555710
25. Nitrovasodilators, low-dose aspirin, other nonsteroidal antiinflammatory drugs, and the risk of upper gastrointestinal bleeding. Lanas A, Bajador E, Serrano P, Fuentes J, Carreno S, Guardia J, Sanz M, Montoro M, Sainz R, New Engl J Med 2000 343 834 839 10.1056/NEJM200009213431202 10995862
26. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. Chan FK, Hung LC, Suen BY, Wu JC, Lee KC, Leung VK, Hui AJ, To KF, Leung WK, Wong VW, et al. New Engl J Med 2002 347 2104 2110 10.1056/NEJMoa021907 12501222 (Pubitemid 36015122)
27. Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications. Lai KC, Chu KM, Hui WM, Wong BC, Hu WH, Wong WM, Chan AO, Wong J, Lam SK, Am J Med 2005 118 1271 1278 10.1016/j.amjmed.2005.04.031 16271912 (Pubitemid 41566529)
28. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. Chan FK, Lanas A, Scheiman J, Berger MF, Nguyen H, Goldstein JL, Lancet 2010 376 173 179 10.1016/S0140-6736(10)60673-3 20638563
29. Rationale, design, and governance of Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen (PRECISION), a cardiovascular end point trial of nonsteroidal antiinflammatory agents in patients with arthritis. Becker MC, Wang TH, Wisniewski L, Wolski K, Libby P, Luscher TF, Borer JS, Mascette AM, Husni ME, Solomon DH, et al. Am Heart J 2009 157 606 612 10.1016/j.ahj.2008.12.014 19332185
30. Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen (PRECISION). Pfizer and The Cleveland Clinic, Clinicaltrials.gov [internet]. National Library of Medicine (US). 2006- [cited June 2 2011] NLM Identifier NCT00346216 Available from: http://www. clinicaltrials.gov/ct2/show/study/NCT00346216?term=PRECISION+celecoxib&rank= 1 accessed on January 25, 2012
31. General practitioners' use of guidelines in the consultation and their attitudes to them. Watkins C, Harvey I, Langley C, Gray S, Faulkner A, Br J Gen Pract 1999 49 11 15 10622009 (Pubitemid 29027494)
32. Clinical guidelines: potential benefits, limitations, and harms of clinical guidelines. Woolf SH, Grol R, Hutchinson A, Eccles M, Grimshaw J, BMJ 1999 318 527 530 10.1136/bmj.318.7182.527 10024268 (Pubitemid 29189000)
33. Strategies to optimize treatment with NSAIDs in patients at risk for gastrointestinal and cardiovascular adverse events. Scheiman JM, Hindley CE, Clin Ther 2010 32 667 677 10.1016/j.clinthera.2010.04.009 20435236
34. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Antman EM, Bennett JS, Daugherty A, Furberg C, Roberts H, Taubert KA, Circulation 2007 115 1634 1642 10.1161/CIRCULATIONAHA.106.181424 17325246 (Pubitemid 46648649)